February 10th 2024
Susan Marie Lang, MD, discusses the incidence of ocular toxicity following treatment with mirvetuximab soravtansine in ovarian cancer.
January 26th 2024
Susan Marie Lang, MD, discusses the incidence of real-world ocular toxicity during treatment with mirvetuximab soravtansine in pretreated ovarian cancer.